Molecular profiling of synchronous and metachronous cancers of the pancreas reveal molecular mimicry between samples from the same patient

Journal of Surgical Research

Volumn 176, Issue 1, 2012, Pages 154-158

  Talbott, Vanessa A ^a   Yeo, Charles J ^a   Brody, Jonathan R ^a   Witkiewicz, Agnieszka K ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

metachronous tumors; molecular markers; multicentricity; pancreatic ductal adenocarcinoma; synchronous tumors

Indexed keywords

CISPLATIN; GEMCITABINE; GENOMIC DNA; K RAS PROTEIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLONE; FEMALE; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; LASER MICRODISSECTION; MALE; MOLECULAR MECHANICS; PANCREAS ADENOCARCINOMA; PANCREATICODUODENECTOMY; PRIORITY JOURNAL; SPLENECTOMY;

ADENOCARCINOMA; AGED; CHEMORADIOTHERAPY, ADJUVANT; DNA, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA2; GENES, RAS; HUMANS; LOSS OF HETEROZYGOSITY; MOLECULAR MIMICRY; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; PANCREATECTOMY; PANCREATIC NEOPLASMS;

EID: 84862001313     PISSN: 00224804     EISSN: 10958673     Source Type: Journal    
DOI: 10.1016/j.jss.2011.09.043     Document Type: Article

References (34)

1. Altekruse SF, Kosary CL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2007, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/ 1975-2007/. Accessed on January 1, 2011.
2. K.Y. Bilimoria, D.J. Bentrem, and C.Y. Ko National failure to operate on early stage pancreatic cancer Ann Surg 246 2007 173
3. M. Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605
4. D. Brinkmann, A. Ryan, and A. Ayhan A molecular genetic and statistical approach for the diagnosis of dual-site cancers J Nat Cancer Inst 96 2004 1441
5. S.J. Diaz-Cano, A. Blanes, and H.J. Wolfe PCR techniques for clonality assays Diagn Mol Pathol 10 2001 24
6. M. Tang, Y. Pires, and M. Schultz Microsatellite analysis of synchronous and metachronous tumors: A tool for double primary tumor and metastasis assessment Diagn Mol Pathol 12 2003 151
7. S. Dacic, D.N. Ionescu, and S. Finkelstein Patterns of allelic loss of synchronous adenocarcinomas of the lung Am J Surg Pathol 29 2005 897
8. R.S. Saad, K.L. Denning, and S.D. Finkelstein Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma Mod Pathol 21 2008 1200
9. S.L. Dykes, H. Qui, and D.A. Rothenberger Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer Cancer 98 2003 48
10. S. Izumi, S. Nakamura, and S. Mano Resection of four synchronous invasive ductal carcinomas in the pancreas head and body associated with pancreatic intraepithelial neoplasia: Report of a case Surg Today 39 2009 1091
11. J.A. van Heerden, W.H. ReMine, and L.H. Weiland Total pancreatectomy for ductal adenocarcinoma of the pancreas. Mayo Clinic experience Am J Surg 142 1981 308
12. A.F. Tryka, and J.R. Brooks Histopathology in the evaluation of total pancreatectomy for ductal carcinoma Ann Surg 190 1979 373
13. I. Ihse, P. Lilja, and B. Arnesjo Total pancreatectomy for cancer. An appraisal of 65 cases Ann Surg 186 1977 675
14. K. Motojima, T. Urano, and Y. Nagata Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma Ann Surg 217 1993 138
15. M. Tanaka, S. Chari, and V. Adsay International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas Pancreatology 6 2006 17
16. T. Augustin, and T.J. Vandermeer Intraductal papillary mucinous neoplasm: A clinicopathologic review Surg Clin North Am 90 2010 377
17. M. Yamano, H. Fujii, and T. Takagaki Genetic progression and divergence in pancreatic carcinoma Am J Pathol 156 2000 2123
18. D.J. Brat, K.D. Lillemoe, and C.J. Yeo Progression of pancreatic intraductal neoplasias to infiltrating adenocarcinoma of the pancreas Am J Surg Pathol 22 1998 163
19. T. Kamisawa, Y. Tu, and N. Egawa Malignancies associated with intraductal papillary mucinous neoplasm of the pancreas World J Gastroenterol 11 2005 5688
20. H. Uehara, A. Nakaizumi, and O. Ishikawa Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas Gut 57 2008 1561
21. M.G. Choi, S.W. Kim, and S.S. Han High incidence of extrapancreatic neoplasms in patients with intraductal papillary mucinous neoplasms Arch Surg 141 2006 51 discussion 56
22. M. Sugiyama, and Y. Atomi Extrapancreatic neoplasms occur with unusual frequency in patients with intraductal papillary mucinous tumors of the pancreas Am J Gastroenterol 94 1999 470
23. http://www.redpathip.com/ accessed January 11, 2011.
24. F. Skoulidis, L.D. Cassidy, and V. Pisupati Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer Cancer Cell 18 2010 499
25. H. Fujii, M. Inagaki, and S. Kasai Genetic progression and heterogeneity in intraductal papillary-mucinous neoplasms of the pancreas Am J Pathol 151 1997 1447
26. K. Z'graggen, J.A. Rivera, and C.C. Compton Prevalence of activating K-ras mutations in the evolutionary stages of neoplasia in intraductal papillary mucinous tumors of the pancreas Ann Surg 226 1997 491 discussion 498
27. J. Franko, A.M. Krasinskas, and M.N. Nikiforova Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma J Gastrointest Surg 12 2008 1664 discussion 1672
28. A.R. Venkitaraman Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment Ann Rev Pathol 4 2009 461
29. F.J. Couch, M.R. Johnson, and K.G. Rabe The prevalence of BRCA2 mutations in familial pancreatic cancer Cancer Epidemiol Biomarkers Prev 16 2007 342
30. M. Goggins, M. Schutte, and J. Lu Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas Cancer Res 56 1996 5360
31. E. Gallmeier, E.S. Calhoun, and C. Rago Targeted disruption of FANCC and FANCG in human cancer provides a preclinical model for specific therapeutic options Gastroenterology 130 2006 2145
32. M.S. van der Heijden, J.R. Brody, and D.A. Dezentje In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor Clin Cancer Res 11 2005 7508
33. S. Jones, R.H. Hruban, and M. Kamiyama Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene Science (New York, N.Y) 324 2009 217
34. H.A. Burris III, M.J. Moore, and J. Andersen Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial J Clin Oncol 15 1997 2403